Gwendolyn Wu is a reporter at BioPharma Dive. She covers biotech startups, venture capital, and the supporting ecosystem, with a strong focus on medicine, healthcare, pharmaceuticals, and medical technology. Gwendolyn's work has been featured in prominent outlets including the Houston Chronicle, San Francisco Chronicle, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Gwendolyn Wu's coverage primarily revolves around the biotechnology industry, particularly focusing on press releases and private sector announcements. She is likely to be interested in pitches related to groundbreaking developments in biotech, such as new drug approvals, IPO filings, or significant funding rounds.
Given her focus on business (16%) within the context of biotechnology (45%), she may also be receptive to news about mergers and acquisitions involving biotech companies or innovative business strategies within the industry.
As Gwendolyn does not have a specific geographic focus mentioned, it is likely that she covers global developments in the field of biotechnology. Therefore, international perspectives and stories with broad relevance are more likely to resonate with her reporting interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.
By: Gwendolyn Wu
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
By: Gwendolyn Wu
Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.
Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.
Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.
